The Company has announced a year-end update in five clinical trials using the Company’s therapeutic products, LAPP and MAPP multi-antigen targeted T cell (MultiTAA) therapies and TPIV200, its Folate Receptor Alpha (FRα) peptide cancer vaccine product candidate.
Marker Therapeutics has emerged out of a merger with Tapimmune to push forward new cell-based cancer vaccines.
President and CEO, Peter L. Hoang, will be participating at the Tumor Targeted Lymphocyte Summit.
Data from three abstracts—including an oral presentation—were accepted for presentation at the 60th American Society of Hematology Annual Meeting (ASH 2018).
“Over my career, I’ve had the chance to work with many great companies, a number of which have had a major impact within the biotech sector that led to great advances in patient care. However, I believe Marker Therapeutics’ patient data are truly exceptional, generating excellent complete response rates in a meaningful number of patients to date. ,” said Mr. Kim.
The U.S. Department of Defense (DoD) has awarded Mayo Clinic researchers $11 million to conduct a Phase 2 trial investigating the TPIV110 vaccine, in combination with Herceptin (trastuzumab), as a therapy for women with HER2-positive breast cancer.
President and CEO, Peter L. Hoang, will be participating in several healthcare conferences this month.
“We are excited and fortunate to have these four highly accomplished professionals join our team,” commented Marker Therapeutics’ President & CEO Peter L. Hoang.
The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 18th begins trading under the ticker (NASDAQ: MRKR), retiring TapImmune’s ticker (TPIV).
Marker Therapeutics, Inc. President and CEO, Peter L. Hoang, will be participating in conferences next week.